logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Triveni Bio Launches With $92 Million Series A Financing To Advance Genetics-Informed Precision Medicines For The Treatment Of Immunological And Inflammatory (I&I) Disorders

Oct 26, 2023•about 2 years ago

Amount Raised

$92 Million

Round Type

series a

WalthamBiotechnologyHealth Care

Investors

Alexandria Venture InvestmentsPolaris PartnersInvusViking Global InvestorsOrbi MedCormorant Asset ManagementAtlas Venture

Description

Triveni Bio Inc., a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders, today announced a $92 million series A financing co-led by Atlas Venture and Cormorant Asset Management, with participation from OrbiMed, the private equity business of Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments, and other investors.

Company Information

Company

Triveni Bio

Location

Waltham, Massachusetts, United States

About

Triveni Bio is a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. The company’s approach establishes proof-of-concept at the earliest stages of drug development. Through a strong understanding of genetics and mechanistic biology, our pipeline is powered for indication expansion where we know we can have the most impact.

Related People

2 contacts

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech